Found this encouraging....
http://bloodjournal....362889.abstract
Abstract
Success of tyrosine kinase inhibitors (TKIs) in Chronic Myeloid Leukemia (CML) has given patients hope for a long disease-free-survival. A longer-survival raises the question of late-effects including the development of another malignancy. Records of 1445 patients with CML/Myeloproliferative Neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate the frequency and characteristics of second malignancies (other than AML, ALL or MDS). The number of second cancers was compared with the number expected from the Surveillance, Epidemiology, and End Results database. After a median follow-up of 107 (range 13-362) months after CML/MPN diagnosis, 66 (4.6%) patients developed 80 second cancers, including skin (31%), prostate (15%), melanoma (13%), digestive system (10%), kidney (4%), thyroid (4%), breast (3%), CLL (3%), hepatobiliary (3%) and other cancers (14%). Excluding non-melanoma skin cancers, 55 second cancers were seen in 51 (3.5%) of all patients treated. The risk of second cancer was lower than expected risk (observed-to-expected ratio 0.6, 95% confidence interval 0.44-0.81). Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. There is no evidence at the moment to suggest that exposure to TKI increases the risk of developing second cancers.
